Author

О. В. Занозина

Observed names: O V Zanozina, O. V. Zanozina, O.V. Zanozina, O.V. Zanozina ( Zanozina, Ol'ga Vladimirovna Zanozina, Olga V Zanozina, Olga V. Zanozina, Olga Zanozina, Zanozina Olga Vladimirovna, Занозина Ольга Владимировна, Занозина, О.В., О В Занозина, О. V. Zanozina, О.V. Zanozina, О.В. Занозина, Ольга Владимировна Занозина

Institutions: Privolzhsky Research Medical University, Nizhny Novgorod Regional Clinical Hospital named after Semashko

Observed institutions: Privolzhsky Research Medical University, Nizhny Novgorod Regional Clinical Hospital named after Semashko, Nizhny Novgorod Academy of the Ministry of Internal Affairs of Russia, Ministry of Health of the Russian Federation, Ural Branch of the Russian Academy of Sciences, Izhevsk State Medical Academy, Udmurt Federal Research Center, Ural Branch of the Russian Academy of Sciences

ORCID: 0000-0003-1830-3600

Observed ORCID: 0000-0003-1830-3600

OpenAlex ID: A5064728014

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

2018 · Adrian F Hernandez, Jennifer B Green, et al. · The Lancet · 1,822

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis

2022 · Peter Rossing, Stefan D. Anker, et al. · Diabetes Care · 216

Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes

2023 · Rajiv Agarwal, Wanzhu Tu, et al. · Annals of Internal Medicine · 105

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study

2022 · Peter Rossing, Ellen Burgess, et al. · Diabetes Care · 38

Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: A 16-week, randomized, open-label, parallel-group trial conducted in russia

2007 · Olga Ushakova, Vera Sokolovskaya, et al. · Clinical Therapeutics · 32

Осмотическая активность и безопасность инъекционных форм нестероидных противовоспалительных препаратов

2018 · Александр Ливиевич Ураков, Наталия Александровна Уракова, et al. · Экспериментальная и клиническая фармакология · 7

Genetic Polymorphism in Patients with Newly Diagnosed Type 2 Diabetes Mellitus

2019 · Yu.A. Sorokina, L.V. Lovtsova, et al. · Современные технологии в медицине · 5

The insulin resistance indices: necessity and opportunities in type 2 diabetes mellitus management

2020 · Yu. A. Sorokina, O. V. Zanozina, et al. · Clinical Medicine (Russian Journal) · 3

Влияние Лекарственных Средств На Уровень Белка Клото

2020 · Сорокина, Ю.А., Мосина, А.А., et al. · Russian Agency for Digital Standardization · 2

Relationship of clinical efficacy of glucose lowering agents, gut microbiota, diet, and patient’s genotype in diabetes mellitus type 2

2018 · Aleksandr L. Urakov, Konstantin G. Gurevich, et al. · Reviews on Clinical Pharmacology and Drug Therapy · 2

Gliptins in the Incretin-Based Pharmacotherapy of Diabetes Mellitus: Opportunities and Personalization

2018 · O. V. Zanozina, Yu. A. Sorokina, et al. · Remedium Privolzhje eBooks · 2

cystatin c in the diagnosis oF chronic Kidney disease in Patients with tyPe 2 diabetes MeLLitus

2013 · N.А. Yarkova, Н. Н. Боровков, et al. · Современные технологии в медицине · 2

Significance of certain leukocyte indices in patients with type 2 diabetes who have had novel coronavirus infection

2025 · S. A. Sukhanov, Yu. A. Sorokina, et al. · Meditsinskiy sovet = Medical Council · 1

Contemporary prospects for the use of sodium-glucose cotransporter-2 inhibitors

2024 · A. R. Kondratieva, E. A. Khazova, et al. · Perm Medical Journal · 1

A smart device for smart self-monitoring of glycemia in patients with diabetes

2024 · O. V. Zanozina, Yu. A. Sorokina, et al. · Meditsinskiy sovet = Medical Council · 1

Post-COVID syndrome in patients with type 2 diabetes: definition, epidemiology, pathophysiology, biomarkers and genetic associations

2024 · S. A. Sukhanov, Yu. A. Sorokina, et al. · Meditsinskiy sovet = Medical Council · 1

Возможная Генетическая Предрасположенность К Неврологическим Нарушениям У Больных Сахарным Диабетом 2 Типа После Перенесённой Новой Короновирусной Инфекции

2023 · С. А. Суханов, М. В. Кобалава, et al. · Конференция по лечению и диагностике сахарного диабета «Фундаментальная и клиническая диабетология в 21 веке: от теории к практике» · 1

Cardiovascular pathology and intestinal microbiome relationship: potential targets of pharmacotherapy

2023 · Y. A. Sorokina, N. A. Petunina, et al. · Meditsinskiy sovet = Medical Council · 1

Immunotropic effects of hypoglycemic agents on coronavirus infection: a view from the perspective of pharmacogenetics

2022 · Konstantin G. Gurevich, Yulia A. Sorokina, et al. · Reviews on Clinical Pharmacology and Drug Therapy · 1

Approaches to the therapy of heart failure with reduced ejection fraction. Resolution of an online meeting of the Volga Federal District experts

2021 · A. S. Galyavich, I. V. Fomin, et al. · Russian Journal of Cardiology · 1

Leptin and its receptor gene polymorphism as a target for pharmacotherapy in T2DM and COPD

2021 · Yu. A. Sorokina, O. V. Zanozina, et al. · Meditsinskiy sovet = Medical Council · 1

Комбинированная Фармакотерапия Вагинитов При Беременности

2021 · Гомозов, Г.Н., Волкова, Т.С., et al. · Russian Agency for Digital Standardization · 1

Problem of detection and pharmacological correction of anxious and depressive disorders in patients with type 2 diabetes mellitus

2018 · Yu.A. Sorokina () Sorokina, A.V. Zanozin () Zanozin, et al. · Фарматека · 1

Metformin and vildagliptin combination: A new approach of endothelial nitric oxide synthase activity regulation and metabolism in diabetes mellitus type 2

2018 · Aleksandr L Urakov, Konstantin G Gurevich, et al. · Reviews on Clinical Pharmacology and Drug Therapy · 1

Hypoglycemia and hyperglycemia: potential risks of polypragmasia in type 2 diabetes in hospital settings

2018 · Yu. A. Sorokina, O. V. Zanozina, et al. · Meditsinskiy sovet = Medical Council · 1

Works count: 102

Citation count: 2,255

H-index: 6

I10-index: 5